[Targeting therapy with a drug using temperature-sensitive liposomes entrapped antitumor drug together with localized hyperthermia].
The characteristics and feasibility of targeting therapy with combination of temperature-sensitive liposomes entrapped antitumor drug with localized hyperthermia were discussed on the theoretical as well as experimental basis. An optimum liposome form and a drug for this delivery were proposed as follows: the liposome is LUV which has a phase transition temperature of 41 to 42 degree and the osmotic pressure of the internal aqueous phase is 1.5 or higher than the physiological one, the drug has a large body clearance and has a synergistic effect with hyperthermia. The LUV preparation containing cisplatin was administered to mice together with tumor heating. The uptake of the drug in the tumor (as a criterion of targeting) were 3 to 5 times greater than those of an aqueous cisplatin solution. The tumor responses were well correlated with the drug-targeting.
Ogawa
Y
Y
Pharmaceutics Research Laboratories, Research & Development Division, Takeda Chemical Industries, Ltd.
Toguchi
H
H
D000818:Animals; D002945:Cisplatin / Q000008:administration & dosage*; D003131:Combined Modality Therapy; D004337:Drug Carriers; D006979:Hyperthermia, Induced; D008081:Liposomes; D051379:Mice; D009374:Neoplasms, Experimental / Q000473:pathology / Q000628:therapy*; D051381:Rats; D013696:Temperature
D004337:Drug Carriers; D008081:Liposomes; D002945:Cisplatin